Insider Selling: Maze Therapeutics (NASDAQ:MAZE) Insider Sells $52,437.07 in Stock

Key Points

• Maze Therapeutics insider Phillips Courtney sold 1,981 shares for $52,437 at an average price of $26.47, reducing their position by 18.01%. The sale was made to cover tax withholding related to vested equity awards.
• MAZE shares traded at $26.21, below their 50-day and 200-day moving averages, while the company remains loss-making after reporting quarterly EPS of negative $0.76.
• Analyst sentiment is broadly positive: the stock carries a consensus “Buy” rating and a $66 average price target, despite some sell ratings and recent insider selling.

Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Phillips Courtney sold 1,981 shares of the company's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $26.47, for a total transaction of $52,437.07. Following the completion of the transaction, the insider owned 9,019 shares of the company's stock, valued at approximately $238,732.93. The trade was a 18.01% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Phillips Courtney also recently made the following trade(s):

• On Thursday, September 3rd, Phillips Courtney sold 2,012 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.01, for a total transaction of $52,332.12.

Maze Therapeutics Stock Performance

MAZE traded up $0.34 on Friday, reaching $26.21. The company had a trading volume of 273,266 shares, compared to its average volume of 637,671. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09. Maze Therapeutics, Inc. has a 1 year low of $14.27 and a 1 year high of $53.65. The stock has a market capitalization of $1.46 billion, a PE ratio of -10.40 and a beta of 2.17. The stock has a 50-day moving average price of $28.74 and a 200-day moving average price of $31.20.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.76). As a group, research analysts forecast that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Institutional Trading of Maze Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada grew its stake in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company's stock valued at $27,000 after purchasing an additional 363 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Maze Therapeutics during the fourth quarter worth approximately $43,000. California State Teachers Retirement System lifted its holdings in shares of Maze Therapeutics by 138.0% during the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company's stock worth $55,000 after purchasing an additional 766 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Maze Therapeutics in the 2nd quarter valued at $48,000. Finally, Ameritas Investment Partners Inc. raised its position in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock worth $42,000 after buying an additional 738 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on MAZE shares. Wall Street Zen cut Maze Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. TD Cowen raised shares of Maze Therapeutics to a "strong-buy" rating in a report on Monday, August 24th. BTIG Research reiterated a "buy" rating and issued a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Three investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $66.00.

Maze Therapeutics News Summary

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source